Court’s decision on Namenda ‘hard switch’ could spill over into precedent

Tracy Staton

Last week, a New York judge called a halt on Actavis' plan to pull off the market, throwing off its strategy for switching patients to a newer extended-release version.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS